\n
![\"\"](\"https:\/\/www.newsbeep.com\/nz\/wp-content\/uploads\/2026\/03\/imageForEntry29-YYj.jpg\")
Sam Edwards \/ OJO Images via Getty Images<\/p>\nAfter a career spanning two decades at Bear Stearns, Lehman Brothers, and Morgan Stanley, I gained an institutional perspective on dividend stock investing. My tenure at these premier Wall Street firms exposed me to fundamental analysis, credit evaluation, and risk management practices that directly translate into selecting high-quality dividend-paying companies. Having witnessed firsthand the 2008 financial crisis and its aftermath\u2014including the collapse of Bear Stearns and Lehman Brothers, from which I was fortunately spared as I had left\u2014 I developed an appreciation for balance sheet strength, sustainable payout ratios, and the importance of dividends as a stabilizing force during market turbulence.<\/p>\n
Technological innovation adds further appeal, with breakthroughs in gene therapy, AI diagnostics, GLP-1 drugs, and personalized medicine opening entirely new revenue streams. Many leading companies in the sector have decades of dividend growth and deep economic moats built on patents and regulatory approvals. Taken together, aging populations, recession resilience, and constant innovation make healthcare one of the rare sectors where the long-term growth thesis is nearly structural rather than speculative.<\/p>\n
We screened our 24\/7 Wall St. dividend healthcare research database, looking for stocks with dependable, high yields that still offer significant upside potential and a safety net should the market dive, triggering a correction or a bear market. Five top companies with reliable, regularly increasing dividends stand out as smart choices right now.<\/p>\n
Why do we cover healthcare dividend stocks?
\nSam Edwards \/ OJO Images via Getty Images<\/p>\n
Healthcare offers one of the most compelling long-term investment sectors for several fundamental reasons. The most powerful tailwind is simple demographics \u2014 the global population is aging rapidly, with the number of people over 65 set to double in the coming decades, driving sustained and largely inelastic demand for medical services, pharmaceuticals, and devices. Unlike most industries, healthcare demand doesn\u2019t dry up in recessions, giving the sector a defensive quality that few others can match.<\/p>\n
Bristol-Myers Squibb<\/p>\n
Bristol Myers Squibb (NYSE: BMY<\/a>) is a global biopharmaceutical company committed to discovering, developing, and delivering transformative medicines for patients with serious diseases across oncology, hematology, immunology, cardiovascular disease, neuroscience, and other therapeutic areas. This remains a solid pharmaceutical stock to own in the long term, offering an outstanding entry point with a reliable 4.10% dividend.<\/p>\n Its platforms comprise chemically synthesized or small-molecule drugs, including protein degraders, as well as biologics produced through biological processes. These platforms also encompass ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics.<\/p>\n Small-molecule drugs are typically administered orally in tablet or capsule form, although other drug-delivery mechanisms are also used. Biologics are usually administered by injection or intravenous infusion.\u00a0CAR-T cell therapies are administered by intravenous infusion.<\/p>\n Its growth portfolio includes:<\/p>\n Opdivo Bristol-Myers Squibb\u2019s legacy portfolio includes:<\/p>\n Eliquis UBS has a Buy rating with a $70 price target.<\/p>\n Healthpeak Properties<\/p>\n This leading company invests in real estate in the healthcare industry, including senior housing, life sciences facilities, and medical offices. Healthpeak Properties (NYSE: DOC<\/a>) is a fully integrated real estate investment trust (REIT) with a solid 7.01% dividend. The stock is recommended by Morningstar\u2019s chief U.S. market strategist, who rates it a five-star stock trading at a discount to fair value with a very dependable yield.<\/p>\n The company acquires, develops, owns, leases, and manages healthcare real estate across the United States. It owns, operates, and develops real estate focused on healthcare discovery and delivery. Its\u00a0segments include:<\/p>\n Lab The Outpatient medical segment owns, operates, and develops outpatient medical facilities, hospitals, and laboratory facilities.<\/p>\n The Lab segment properties contain laboratory and office space, and are leased primarily to:<\/p>\n Biotechnology Its CCRC segment comprises a retirement community offering independent living, assisted living, memory care, and skilled nursing units, providing a continuum of care within an integrated campus.<\/p>\n Evercore ISI has an Outperform rating with a $19 target price.<\/p>\n Merck<\/p>\n Developing and producing medicines, vaccines, biological therapies, and animal health products, Merck (NYSE: MRK<\/a>) is not just a healthcare company but a global force in the industry. This healthcare giant is a no-brainer, paying a solid 2.79% dividend and raising it for 15 consecutive years. The company operates through two segments.<\/p>\n The Pharmaceutical segment offers human health pharmaceutical products in:<\/p>\n Oncology The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, health management solutions and services, and digitally connected identification, traceability, and monitoring products.<\/p>\n Merck serves:<\/p>\n Drug wholesalers Merck\u2019s growth is a result of its efforts and strategic collaborations. The company works with AstraZeneca, Bayer, Eisai, Ridgeback Biotherapeutics, and Gilead Sciences\u00a0to jointly develop and commercialize long-acting HIV treatments, demonstrating a commitment to innovation and growth.<\/p>\n Deutsche Bank has a Buy rating with a $150 target price.<\/p>\n Pfizer<\/p>\n
\nOpdivo Qvantig
\nOrencia
\nYervoy
\nReblozyl
\nOpdualag<\/p>\n
\nRevlimid
\nPomalyst\/Imnovid
\nSprycel
\nAbraxane<\/p>\n
\nOutpatient medical
\nContinuing care retirement community (CCRC)<\/p>\n
\nMedical device and pharmaceutical companies
\nScientific research institutions
\nGovernment agencies
\nOrganizations involved in the life science industry<\/p>\n
\nHospital acute care
\nImmunology
\nNeuroscience
\nVirology
\nCardiovascular
\nDiabetes
\nVaccine products, such as preventive pediatric, adolescent, and adult vaccines<\/p>\n
\nRetailers
\nHospitals
\nGovernment agencies
\nManaged healthcare providers, such as health maintenance organizations
\nPharmacy benefit managers and other institutions
\nPhysicians
\nPhysician distributors
\nVeterinarians
\nAnimal producers<\/p>\n